Publication Type : Journal Article
Publisher : Journal of Clinical and Experimental Hepatology
Source : Journal of Clinical and Experimental Hepatology
Url : https://www.jcehepatology.com/article/S0973-6883(24)00601-7/
Campus : Kochi
School : School of Medicine
Department : Gastroenterology
Year : 2024
Abstract : Background and Aim: Patients with advanced cirrhosis develop dilutional hyponatremia (<130meq/dL) due to non-osmotic hypersecretion of arginine vasopressin (AVP). Hyponatremia is an independent risk factor for mortality. We undertook this study to ascertain the efficacy of tolvaptan in increasing serum sodium in cirrhosis with hyponatremia.
Cite this Research Publication : Valsan A, Mohamed Z, Malayil G, Paul A, Sudhindran S, Verma N, Unnikrishnan G, Koshy A, Balakrishnan D, Kumar L, Madathil S., "A placebo controlled, randomized, double blinded trial to evaluate the use of Tolvaptan for correction of hyponatremia in liver cirrhosis patients (SCOTcH trial)," Journal of Clinical and Experimental Hepatology, Volume 14, 1019442024 Jan 1, 2024.